Allspring Global Investments Holdings LLC Sells 12,211 Shares of RxSight, Inc. (NASDAQ:RXST)

Allspring Global Investments Holdings LLC lessened its holdings in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 7.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 162,730 shares of the company's stock after selling 12,211 shares during the period. Allspring Global Investments Holdings LLC owned 0.44% of RxSight worth $8,044,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in RXST. CWM LLC lifted its stake in shares of RxSight by 727.5% in the 2nd quarter. CWM LLC now owns 422 shares of the company's stock worth $25,000 after acquiring an additional 371 shares during the period. Quest Partners LLC acquired a new stake in RxSight in the second quarter worth approximately $41,000. Larson Financial Group LLC bought a new position in RxSight during the 1st quarter valued at $51,000. Amalgamated Bank increased its position in shares of RxSight by 21.3% during the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company's stock valued at $71,000 after purchasing an additional 207 shares during the period. Finally, Canada Pension Plan Investment Board bought a new stake in shares of RxSight in the 2nd quarter worth $156,000. 78.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at RxSight

In other RxSight news, insider Ilya Goldshleger sold 9,000 shares of the company's stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $39.25, for a total value of $353,250.00. Following the transaction, the insider now directly owns 42,246 shares of the company's stock, valued at $1,658,155.50. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last 90 days, insiders sold 43,110 shares of company stock valued at $2,059,584. Insiders own 9.36% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on RXST. Wells Fargo & Company decreased their target price on RxSight from $68.00 to $54.00 and set an "overweight" rating for the company in a research note on Tuesday, August 6th. BTIG Research lifted their price objective on shares of RxSight from $72.00 to $73.00 and gave the stock a "buy" rating in a research note on Monday, July 15th. Oppenheimer cut their target price on shares of RxSight from $72.00 to $65.00 and set an "outperform" rating for the company in a research note on Tuesday, August 6th. Needham & Company LLC restated a "buy" rating and issued a $66.00 price target on shares of RxSight in a research report on Friday, September 13th. Finally, Stifel Nicolaus decreased their target price on RxSight from $70.00 to $65.00 and set a "buy" rating on the stock in a report on Tuesday, August 6th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $60.14.

RxSight Trading Up 1.6 %

NASDAQ:RXST traded up $0.81 on Friday, hitting $50.38. 227,412 shares of the company's stock traded hands, compared to its average volume of 468,720. The company has a market cap of $1.86 billion, a PE ratio of -39.98 and a beta of 1.20. RxSight, Inc. has a 1 year low of $20.66 and a 1 year high of $66.54. The firm has a 50-day moving average price of $51.96 and a 200-day moving average price of $53.70.

RxSight (NASDAQ:RXST - Get Free Report) last released its quarterly earnings data on Monday, August 5th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.06. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. The firm had revenue of $34.89 million for the quarter, compared to analyst estimates of $32.33 million. During the same quarter in the prior year, the business earned ($0.40) EPS. The company's revenue for the quarter was up 67.6% compared to the same quarter last year. On average, research analysts forecast that RxSight, Inc. will post -0.81 EPS for the current fiscal year.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.